Gene Logic, Inc. has entered into a drug repositioning and development agreement with Merck Serono to seek alternative development paths for several Merck Serono drug candidates that were discontinued or de-prioritized in clinical trials for reasons other than safety.     Under the agreement Gene Logic will receive success-based milestones and royalties similar to those paid for development-stage in-licensing deals. Gene Logic also has the option gain exclusive license to any drug candidate i...